PLEXPRIMER
LIVE

Serial Number

79183455

Owner

SpeeDx Pty Ltd

Attorney

David Perry

Filing Date

Sep 17, 2015

Add to watchlist:

No watchlists yet
View on USPTO

PLEXPRIMER Trademark

Serial Number: 79183455 • Registration: 5215665

PLEXPRIMER is a trademark filed by SpeeDx Pty Ltd on September 17, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

SpeeDx Pty Ltd (21 trademarks)

Suite G16, National Innovation Centre,

Entity Type: 82

Trademark Details

Filing Date

September 17, 2015

Registration Date

June 6, 2017

Published for Opposition

March 21, 2017

Cancellation Date

December 22, 2023

Goods & Services

Chemicals used in industry, science, photography; chemicals used in agriculture, horticulture and forestry except fungicides, herbicides, insecticides, and parasiticides; chemical reagents and reactants in this class for non-medical purposes; enzymes for industrial purposes, namely, for use in the biotechnology industry; nucleic acid sequences, other than medical and veterinary purposes; nucleic recombinant acids; acids, namely, inorganic acids; organic acids for use in the biotechnology industry; DNA polymerase, other than medical and veterinary purposes; chemicals used in food processing and screening; chemicals used in environmental monitoring

Pharmaceutical and veterinary preparations and substances for the diagnosis of diseases or detection or identification of pathogens for medical and veterinary purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use; chemical preparations containing enzymes for medical purposes for the diagnosis of diseases or detection or identification of pathogens; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes for the diagnosis of diseases or detection or identification of pathogens; enzymes for pharmaceutical, veterinary and medical purposes; medical kits in this class consisting of catalytic DNA molecules and associated detection reagents for the diagnosis of diseases, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; diagnostic reagents for medical or veterinary use; biological chemical test kits for medical laboratory use in analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders

Surgical, medical and veterinary apparatus and instruments, namely, surgical apparatus and instruments for medical or veterinary use; diagnostic testing apparatus and instruments for medical purposes, namely, for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; point of care medical devices for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; medical screening apparatus in this class for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Sep 20, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Aug 31, 2024 INTS
INVALIDATION PROCESSED
Aug 31, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 23, 2024 INTR
CANCELLED SECTION 71
Dec 22, 2023 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 6, 2022 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 14, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 14, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 6, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 6, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 21, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 21, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Mar 17, 2017 GPNX
NEW REPRESENTATIVE AT IB RECEIVED
Mar 10, 2017 NREP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 1, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 1, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 1, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 13, 2017 PREV
NEW REPRESENTATIVE AT IB RECEIVED
Feb 10, 2017 NREP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 1, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 1, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 1, 2017 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 19, 2016 GNFN
FINAL REFUSAL E-MAILED
Dec 19, 2016 GNFR
FINAL REFUSAL WRITTEN
Dec 19, 2016 CNFR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 16, 2016 NREP
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 14, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 14, 2016 CRFA
ASSIGNED TO LIE
Dec 9, 2016 ALIE
NOTICE OF REVIVAL - MAILED
Nov 29, 2016 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 28, 2016 TROA
PETITION TO REVIVE-GRANTED
Nov 28, 2016 PETG
TEAS PETITION TO REVIVE RECEIVED
Nov 28, 2016 PROA
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 3, 2016 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 1, 2016 ABN2
REFUSAL PROCESSED BY IB
Mar 19, 2016 RFNT
APPLICATION FILING RECEIPT MAILED
Mar 4, 2016 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 2, 2016 RFCS
REFUSAL PROCESSED BY MPU
Mar 2, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 2, 2016 RFCR
NON-FINAL ACTION WRITTEN
Mar 1, 2016 CNRT
ASSIGNED TO EXAMINER
Feb 29, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 29, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 25, 2016 REPR